Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)

被引：0
作者：
Vermersch, P. [1 ]
Eralinna, J. [2 ]
Nicholas, R. [3 ,4 ]
Oreja-Guevara, C. [5 ]
Siva, A. [6 ]
Van Wijmeersch, B. [7 ,8 ]
Wiendl, H. [9 ]
Buffels, R. [10 ]
Wei, W. [10 ]
Comi, G. [11 ]
机构：
[1] Univ Lille, Lille, France
[2] NEO Res, Turku, Finland
[3] Imperial Coll Healthcare NHS Trust, London, England
[4] Imperial Coll, London, England
[5] Hosp Clin San Carlos, Madrid, Spain
[6] Istanbul Univ, Cerrahpasa Fac Med, Cerrahpasa, Turkey
[7] Univ Hasselt, Overpelt, Belgium
[8] Rehabil & MS Ctr, Overpelt, Belgium
[9] Univ Munster, Munster, Germany
[10] F Hoffmann Roche Ltd, Basel, Switzerland
[11] Univ Vita Salute San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P035
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [41] The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    Devonshire, V.
    Lapierre, Y.
    Macdonell, R.
    Ramo-Tello, C.
    Patti, F.
    Fontoura, P.
    Suchet, L.
    Hyde, R.
    Balla, I.
    Frohman, E. M.
    Kieseier, B. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (01) : 69 - 77
  • [42] Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 study
    Bergh, F. Then
    Singer, B. A.
    Drulovic, J.
    Bidollari, I.
    Chen, H.
    Englishby, R.
    Hanna, J.
    Kandinov, B.
    Lopez-Bresnahan, M.
    Leigh-Pemberton, R.
    Miller, C.
    Mokliatchouk, O.
    Shafer, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 861 - 862
  • [43] Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Efficacy and Safety Results From the Phase 3 EVOLVE-MS-1 Study
    Arnold, Douglas L.
    LaGanke, Christopher
    Obradovic, Dragana
    Gudesblatt, Mark
    Yang, Lili
    Miller, Catherine
    Leigh-Pemberton, Richard
    Lopez-Bresnahan, Maria
    Kandinov, Boris
    Wolinsky, Jerry S.
    NEUROLOGY, 2019, 92 (15)
  • [44] Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
    Naismith, Robert T.
    Wolinsky, Jerry S.
    Wundes, Annette
    LaGanke, Christopher
    Arnold, Douglas L.
    Obradovic, Dragana
    Freedman, Mark S.
    Gudesblatt, Mark
    Ziemssen, Tjalf
    Kandinov, Boris
    Bidollari, Ilda
    Lopez-Bresnahan, Maria
    Nangia, Narinder
    Rezendes, David
    Yang, Lili
    Chen, Hailu
    Liu, Shifang
    Hanna, Jerome
    Miller, Catherine
    Leigh-Pemberton, Richard
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (13) : 1729 - 1739
  • [45] RELAPSE RATES AND SYMPTOM MANAGEMENT AMONG PATIENTS RECEIVING NATALIZUMAB AND OTHER DISEASE-MODIFYING THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Lee, L.
    Pike, J.
    Kendter, J.
    Campagnolo, D.
    Jones, E.
    Naoshy, S.
    VALUE IN HEALTH, 2016, 19 (07) : A427 - A427
  • [46] Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: Results of a five-year brain MRI study
    Khan, Omar
    Bao, Fen
    Shah, Megha
    Caon, Christina
    Tselis, Alexandros
    Bailey, Ronald
    Silverman, Bruce
    Zak, Imad
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 312 (1-2) : 7 - 12
  • [47] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Yin, M.
    Leppert, D.
    Glanzmann, R.
    Tinbergen, J.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S194 - S195
  • [48] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Timothy Spelman
    William L. Herring
    Yuanhui Zhang
    Michael Tempest
    Isobel Pearson
    Ulrich Freudensprung
    Carlos Acosta
    Thibaut Dort
    Robert Hyde
    Eva Havrdova
    Dana Horakova
    Maria Trojano
    Giovanna De Luca
    Alessandra Lugaresi
    Guillermo Izquierdo
    Pierre Grammond
    Pierre Duquette
    Raed Alroughani
    Eugenio Pucci
    Franco Granella
    Jeannette Lechner-Scott
    Patrizia Sola
    Diana Ferraro
    Francois Grand’Maison
    Murat Terzi
    Csilla Rozsa
    Cavit Boz
    Raymond Hupperts
    Vincent Van Pesch
    Celia Oreja-Guevara
    Anneke van der Walt
    Vilija G. Jokubaitis
    Tomas Kalincik
    Helmut Butzkueven
    PharmacoEconomics, 2022, 40 : 323 - 339
  • [49] Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Spelman, Timothy
    Herring, William L.
    Zhang, Yuanhui
    Tempest, Michael
    Pearson, Isobel
    Freudensprung, Ulrich
    Acosta, Carlos
    Dort, Thibaut
    Hyde, Robert
    Havrdova, Eva
    Horakova, Dana
    Trojano, Maria
    De Luca, Giovanna
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Grammond, Pierre
    Duquette, Pierre
    Alroughani, Raed
    Pucci, Eugenio
    Granella, Franco
    Lechner-Scott, Jeannette
    Sola, Patrizia
    Ferraro, Diana
    Grand'Maison, Francois
    Terzi, Murat
    Rozsa, Csilla
    Boz, Cavit
    Hupperts, Raymond
    Van Pesch, Vincent
    Oreja-Guevara, Celia
    van der Walt, Anneke
    Jokubaitis, Vilija G.
    Kalincik, Tomas
    Butzkueven, Helmut
    PHARMACOECONOMICS, 2022, 40 (03) : 323 - 339
  • [50] Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison
    Hutchinson, Michael
    Fox, Robert J.
    Havrdova, Eva
    Kurukulasuriya, Nuwan C.
    Sarda, Sujata P.
    Agarwal, Sonalee
    Siddiqui, Mohd Kashif
    Taneja, Ankush
    Deniz, Baris
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (04) : 613 - 627
12345